AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.058

-0.005-7.94%

Volume:2.37M

Turnover:141.04K

Market Cap:30.92M

PE:-0.18

High:0.062

Open:0.062

Low:0.057

Close:0.063

52wk High:0.460

52wk Low:0.057

Shares:533.09M

Float Shares:254.20M

Volume Ratio:1.16

T/O Rate:0.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.323

EPS(LYR):-0.323

ROE:-313.99%

ROA:-123.50%

PB:3.43

PE(LYR):-0.18

Loading ...

Overview Company News Filings

Company Profile

Company Name:

IMUGENE LTD

Exchange:

ASX

Establishment Date:

- -

Employees:

14

Office Location:

4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia

Website:

http://www.imugene.com

Zip Code:

2000

Phone:

Fax:

61 2 9423 0881

Introduction:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/IMU.AU/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.058,"timestamp":1789020720000,"preClose":0.063,"halted":0,"volume":2370473,"delay":0,"changeRate":-0.07936507936507932,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":533088258,"eps":-0.323022,"marketStatus":"Closed","change":-0.005,"latestTime":"09-10 16:12:00 AEST","open":0.062,"high":0.062,"low":0.057,"amount":141039,"amplitude":0.079365,"askPrice":0.059,"askSize":62201,"bidPrice":0.058,"bidSize":100967,"shortable":3,"etf":0,"ttmEps":-0.323022,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.063,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.15905,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMU.AU","preClose":0.063,"auctionPrice":0.058,"auctionVolume":122143,"auctionTime":1789020550131,"referencePrice":0.058,"referenceTime":1789030800651,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020550131}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-123.50%","roe":"-313.99%","lyrEps":-0.323022,"volumeRatio":1.15905,"shares":533088258,"dividePrice":0,"high":0.062,"amplitude":0.079365,"preClose":0.063,"low":0.057,"week52Low":0.057,"pbRate":"3.43","psRate":"14.82","week52High":0.46,"institutionHeld":0,"latestPrice":0.058,"committee":0.237583,"eps":-0.323022,"divideRate":0,"volume":2370473,"delay":0,"ttmEps":-0.323022,"open":0.062,"prevYearClose":0.365,"prevWeekClose":0.069,"prevMonthClose":0.068,"prevQuarterClose":0.115,"fiveDayClose":0.066,"twentyDayClose":0.083,"sixtyDayClose":0.095},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":11113368,"employeeNum":14,"address":"4-6 Bligh Street,Suite 12.01, Level 12,Sydney,New South Wales,Australia","zipCode":"2000","officePhone":"61 2 9423 0881","officeFax":"61 2 9423 0881","fiscalYearEnd":"06-30"},"stockCompanyDetail":{"websiteUrl":"http://www.imugene.com","stockEarnings":[{"period":"1week","weight":-0.0735},{"period":"1month","weight":-0.241},{"period":"3month","weight":-0.3077},{"period":"6month","weight":-0.6595},{"period":"1year","weight":-0.7667},{"period":"ytd","weight":-0.8274}],"compareEarnings":[{"period":"1week","weight":-0.0105},{"period":"1month","weight":-0.0233},{"period":"3month","weight":0.0454},{"period":"6month","weight":0.0554},{"period":"1year","weight":0.096},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.034991},{"month":2,"riseRate":0.291667,"avgChangeRate":-0.044685},{"month":3,"riseRate":0.416667,"avgChangeRate":0.028881},{"month":4,"riseRate":0.25,"avgChangeRate":-0.014779},{"month":5,"riseRate":0.125,"avgChangeRate":-0.102646},{"month":6,"riseRate":0.625,"avgChangeRate":0.170292},{"month":7,"riseRate":0.5,"avgChangeRate":0.036442},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.017148},{"month":9,"riseRate":0.458333,"avgChangeRate":0.044309},{"month":10,"riseRate":0.541667,"avgChangeRate":0.1478},{"month":11,"riseRate":0.291667,"avgChangeRate":0.035512},{"month":12,"riseRate":0.25,"avgChangeRate":-0.058143}],"exchange":"ASX","name":"IMUGENE LTD","nameEN":"IMUGENE LTD"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":null}}